People · Operator
Named in public records as an officer, director or promoter · active 2015–2018 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dimension Therapeutics, Inc. | — | Other Technology | Series C | $94.5M | $2.0B | 2015 |
| Akriveia Therapeutics, LLC | — | Biotechnology | Series A | $7.5M | $108.5M | 2016 |
Benjamin Auspitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Benjamin Auspitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Beck | 2 | 7 |
| Rishi Gupta | 1 | 12 |
| Annalisa Jenkins | 1 | 8 |
| David Grayzel | 1 | 6 |
| Donald J. Hayden, Jr. | 1 | 5 |
| Jay K. Hachigian | 1 | 5 |
| Donald J Hayden | 1 | 3 |
| Donald Hayden | 1 | 3 |
| Michael Gladstone | 1 | 3 |
| Simon Tomlinson | 1 | 2 |
| Benjamin J. Auspitz | 1 | 1 |
| Allan J. Fox | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.